Field Trip FT-104 Phase Ia Safety Trial

Field Trip Health have developed a novel psychedelic compound FT-104. FT-104 is a synthetic serotonin-2A (5HT2A) agonist whose active component has serotonin-2A potency similar to psilocybin however, FT-104 is expected to produce a reliably shorter duration of psychoactivity (2-3 hours) than psilocybin, and has high bioavailability after administration.

Field Trip are conducting preclinical activities with FT-104 which will enable commencement of Phase I trials in early 2022.

The Phase Ia trial aims to determine the safety, pharmacokinetics, and pharmacodynamic parameters in healthy individuals or patients.

Topic Healthy Subjects
Compound Psilocybin
Country Canada
Visit trial
Status Planned
Results Published
Chance of happening 69%
Design Open
Type Interventional
Generation Second
Sex All
Therapy No

Trial Details



NCT Number

Sponsors & Collaborators

Field Trip
Field Trip is a company that offers psychedelics therapies. It has several locations (US/CA) that provides ketamine-assisted therapy. It has raised $19.5M in Series A & B funding rounds.

Data attribution

A large set of the trials in our database are sourced from ClinicalTrials.gov (CTG). We have modified these post to display the information in a more clear format or to correct spelling mistakes. Our database in actively updated and may show a different status (e.g. completed) if we have knowledge of this update (e.g. a published paper on the study) which isn't reflected yet on CTG. If a trial is not sourced from CTG, this is indicated on this page and you can follow the link to the alternative source of information.